Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2017—PerkinElmer has entered into a definitive agreement to acquire Tulip Diagnostics Private Ltd. Tulip, based in Goa, India, is a large domestic provider of in vitro diagnostic reagents, kits, and instruments to diagnostic labs and government and private health care facilities.
April 2017—Aushon BioSystems announced U.S. Patent No. 9,527,085, titled “Apparatus and method for dispensing fluid, semi-solid and solid samples,” was issued by the U.S. Patent and Trademark Office for microarray printing of complex biological and chemical fluids.
April 2017—Sarah Cannon, the cancer institute of Hospital Corporation of America, announced that Genospace LLC, a cloud-based software company focused on advancing personalized medicine, will merge with its organization and become a wholly owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.
April 2017—Singulex has entered into a strategic collaboration with Qiagen to develop companion diagnostics. Through the collaboration, Qiagen will have access to Singulex’s Single Molecule Counting (SMC) immunodiagnostic platform, adding immunoassay capabilities to Qiagen’s existing molecular testing services for the development of companion diagnostics.
March 2017—Streck’s CE-marked antibiotic resistance monitoring and detection (ARM-D) kits are now available. The Streck ARM-D kits, AmpC and β-lactamase, are multiplex real-time PCR reagents for the detection of more than 450 β-lactamase gene targets.
March 2017—LGC Maine Standards added rheumatoid factor to its Validate SP2 calibration verification/linearity test kit. Validate SP2 evaluates albumin, C-reactive protein, haptoglobin, prealbumin, and rheumatoid factor in a human serum base. Each kit is prepared using the CLSI-recommended “equal delta” method for linearity testing and is liquid, ready to use.
March 2017—Qiagen announced it submitted its QuantiFeron-TB Gold Plus, the fourth generation of the modern blood test for detecting tuberculosis infection, for premarket approval by the Food and Drug Administration.
March 2017—Ortho Clinical Diagnostics has submitted a premarket approval application to the U.S. Food and Drug Administration for the Vitros Immunodiagnostic Products HIV Combo Assay for use on the Vitros 3600 immunodiagnostic system.
March 2017—Streck’s Para 12 Extend, a hematology control with three distinct populations of lymphocytes, mononuclears, and granulocytes, is now assayed for the Mindray BC-3600. Varying percentages are also offered in the low abnormal, normal, and high abnormal levels to test the accuracy and precision of the reported white cell populations.
March 2017—LGC Maine Standards’ Validate D-Dimer calibration verification/linearity test kit received FDA 510(k) clearance for use on Stago STA-R Evolution analyzers.
